

## PRESS RELEASE

### Lysogene Secures €5 million in Non-Dilutive Financing

- **Approval received from BRED for a €5 million non-dilutive financing in the form of PGE (State-Guaranteed Loan)**
- **Strengthened cash position with cash runway extended to Q2 2022**

**Paris, France — 10 February 2021 at 08:00am** — Lysogene (FR0013233475 – LYS), a phase 3 gene therapy platform Company targeting central nervous system (CNS) diseases, announced today it has secured a non-dilutive financing of €5 million from BRED in the form of a state-guaranteed loan (PGE). This financing extends the Company's cash runway until Q2 2022, compared to the end of Q4 2021 previously.

This loan is 90% guaranteed by the French State with an initial maturity of 12 months and an option to amortize over 5 years.

**Stéphane Durant des Aulnois, Chief Financial Officer of Lysogene** stated: *"This financing strengthens the Company's cash position at a crucial time in its development with the ongoing Phase 2/3 study evaluating LYS-SAF302 in Sanfilippo disease, the initiation of the clinical trial with LYS-GM101 in GM1 gangliosidosis and the development of the other preclinical programs. We would like to express our gratitude to BRED, which has been on our side since the beginning, and continues to demonstrate its confidence in the Company's development through this financing."*

#### **About Lysogene**

Lysogene is a gene therapy Company focused on the treatment of orphan diseases of the central nervous system (CNS). The Company has built a unique capability to enable a safe and effective delivery of gene therapies to the CNS to treat lysosomal diseases and other genetic disorders of the CNS. A phase 2/3 clinical trial in MPS IIIA in partnership with Sarepta Therapeutics, Inc. is ongoing and a phase 1/3 clinical trial in GM1 gangliosidosis is in preparation. In accordance with the agreements signed between Lysogene and Sarepta Therapeutics, Inc., Sarepta Therapeutics, Inc. will hold exclusive commercial rights to LYS-SAF302 in the United States and markets outside Europe; and Lysogene will maintain commercial exclusivity of LYS-SAF302 in Europe. Lysogene is also collaborating with an academic partner to define the strategy of development for the treatment of Fragile X syndrome, a genetic disease related to autism. [www.lysogene.com](http://www.lysogene.com).



### **Forward Looking Statement**

This press release may contain certain forward-looking statements, especially on the Company's progress of its phase 2-3 clinical trial and cash runway. Although the Company believes its expectations are based on reasonable assumptions, all statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice, (ii) factors beyond the Company's control, (iii) clinical trial results, (iv) increased manufacturing costs and (v) potential claims on its products. These statements may include, without limitation, any statements preceded by, followed by or including words such as "target," "believe," "expect," "aim," "intend," "may," "anticipate," "estimate," "plan," "objective", "project," "will," "can have," "likely," "should," "would," "could" and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company's control that could cause the Company's actual results, performance or achievements to be materially different from the expected results, performance or achievements expressed or implied by such forward-looking statements. A further list and description of these risks, uncertainties and other risks can be found in the Company's regulatory filings with the French Autorité des Marchés Financiers, including in the 2019 universal registration document, registered with the French Markets Authorities on April 30, 2020, under number D.20-0427, and future filings and reports by the Company. Furthermore, these forward-looking statements are only as of the date of this press release. Readers are cautioned not to place undue reliance on these forward-looking statements. Except as required by law, the Company assumes no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future. If the Company updates one or more forward-looking statements, no inference should be drawn that it will or will not make additional updates with respect to those or other forward-looking statements.

This press release has been prepared in both French and English. In the event of any differences between the two texts, the French language version shall supersede.

### **Contacts**

Stéphane Durant des Aulnois

Chief Financial Officer

[stephane.durant-des-aulnois@lysogene.com](mailto:stephane.durant-des-aulnois@lysogene.com)

+ 33 1 41 43 03 99